Atkins H L, Mausner L F, Srivastava S C, Meinken G E, Cabahug C J, D'Alessandro T
Medical Department, Brookhaven National Laboratory, Upton, New York, USA.
J Nucl Med. 1995 May;36(5):725-9.
The physical and biological attributes of 117mSn(4+)-DTPA indicate that it should be an effective agent for palliative therapy of painful bony metastatic disease. The aim of this study was to evaluate whether or not this agent could effectively reduce pain while sparing the hemopoietic marrow from adverse effects.
Fifteen patients (10 males and 5 females) with painful bony metastases from various primary cancers were included in the study. Seven patients received 1.22 to 3.11 MBq/kg of 117mSn intravenously (Group 1) and eight patients received 4.85 to 5.77 MBq/kg (Group 2). All but one were treated as outpatients and followed for a minimum of 2 mo.
In the first group, pain relief was non-assessable in four patients because of death or additional treatment of soft-tissue disease by another modality. One patient had no relief of pain, one had complete relief of pain and one had transient relief of pain. No myelotoxicity was observed. For Group 2, three patients achieved complete relief of pain, two good relief, two partial relief and one began to experience pain relief when he suffered a pathological fracture 2 mo post-treatment. None of these patients had myelotoxicity.
Tin-117m(4+)-DTPA can reduce pain from metastatic disease to bone without inducing adverse reactions related to bone marrow. Further studies are needed to assess tolerance levels for the bone marrow and to evaluate response rates and duration of effect.
117mSn(4+)-二乙三胺五乙酸（DTPA）的物理和生物学特性表明，它应是治疗疼痛性骨转移性疾病姑息治疗的有效药物。本研究的目的是评估该药物是否能有效减轻疼痛，同时使造血骨髓免受不良反应影响。
本研究纳入了15例（10例男性和5例女性）患有各种原发性癌症所致疼痛性骨转移的患者。7例患者静脉注射117mSn，剂量为1.22至3.11 MBq/kg（第1组），8例患者静脉注射剂量为4.85至5.77 MBq/kg（第2组）。除1例患者外，其余均作为门诊患者治疗，随访至少2个月。
在第1组中，由于死亡或通过其他方式对软组织疾病进行额外治疗，4例患者的疼痛缓解情况无法评估。1例患者疼痛未缓解，1例患者疼痛完全缓解，1例患者疼痛短暂缓解。未观察到骨髓毒性。在第2组中，3例患者疼痛完全缓解，2例患者疼痛明显缓解，2例患者部分缓解，1例患者在治疗后2个月发生病理性骨折时开始出现疼痛缓解。这些患者均未出现骨髓毒性。
117m锡（4+）-二乙三胺五乙酸（DTPA）可减轻骨转移性疾病引起的疼痛，且不引起与骨髓相关的不良反应。需要进一步研究以评估骨髓的耐受水平，并评估缓解率和疗效持续时间。
